Proscia® Introduces New Enterprise-Scale Features on the Concentriq® Digital Pathology Platform for Life Sciences Companies

Release coincides with newly-formed collaboration to address growing infrastructure requirements for deploying digital pathology systems

News provided by

Proscia

Nov 12, 2019, 08:00 ET

PHILADELPHIA, Nov. 12, 2019 /PRNewswire-PRWeb/ -- Proscia, a leading provider of digital pathology software, announces the Fall 2019 release of its Concentriq platform, along with a global collaboration with Dell Technologies, to help life sciences companies accelerate the adoption of digital pathology at an enterprise scale. Today's news includes significant product enhancements for more easily managing massive multi-site studies on the Concentriq platform, which is now optimized for cost, scale, and support with Dell Technologies' enterprise solutions.

Life sciences organizations have been on the forefront of digital pathology adoption in an effort to better incorporate pathology data into research and development. While they have amassed millions of images and volumes of associated clinical information, this data largely remains siloed, inaccessible, and dissociated from broader R&D efforts. Proscia introduced the Concentriq image and data management platform to help life sciences organizations adopt and scale digital pathology across the enterprise.

The Fall 2019 release extends Concentriq with new capabilities that drive consistency across pathology data for improved efficiency, visibility, and scalability. With this standardization, pharmaceutical, biotechnology, and contract research organizations (CROs) can streamline the launch and management of concurrent studies involving millions of images across multi-site, multi-role organizations.

The expanded Concentriq platform now provides:

  • Scalable study management – New standard field libraries, templated projects, and expanded roles and permissions create a repeatable framework that simplifies study management and puts new control into the hands of IT administrators and project coordinators.
  • Centralized pathology data management – Concentriq Workspaces offer a single pane of glass that presents data from multiple sources in a unified display, creating a center point of pathology research.
  • Enhanced Global Search – Improved data consistency now enables global search across an entire organization's pathology data.
  • Expanded Image Format Support – Zeiss CZI now joins Akoya Biosciences, Epredia, Hamamatsu, Huron, Leica, and VENTANA Roche as formats supported by Concentriq, allowing organizations to ingest images from a wide array of scanners to meet their specific needs.

"Digital pathology adoption among life sciences organizations is maturing, moving from point-level implementations to widescale rollouts transforming traditional practices across the enterprise," said Coleman Stavish, CTO, Proscia. "We delivered the Fall 2019 release of Concentriq to accelerate this adoption and support highly scalable, image-centric pathology, and our newly-formed collaboration with Dell Technologies furthers this aim."

To support the newly expanded Concentriq platform, Proscia has aligned with Dell Technologies to provide a cost-effective, scalable IT infrastructure for deploying digital pathology solutions. The companies worked together to provide reference architectures for whole-slide image viewing and management, including Proscia's Concentriq platform, combined with high performance compute, scalable storage, and Multi-Cloud capabilities from Dell Technologies. These reference architectures are designed for healthcare and life sciences organizations of any size that must meet today's requirements and anticipate the future needs of organizations as they scale.

"At Dell Technologies, we are committed to advancing the field of pathology with modern solutions to accelerate research breakthroughs and ultimately improve patient outcomes," said David DeAngelis, General Manager, Global Healthcare-Life Sciences, Dell Technologies. "Pathology is among the last fields in medicine to go digital. Together with Proscia, we are delivering the infrastructure and software that laboratories require for successful adoption of digital pathology."

To learn more about how healthcare and life sciences organizations are successfully managing research and development at scale with digital pathology, please join Proscia and Dell Technologies' upcoming webinar "Accelerate and Scale Enterprise Adoption of Digital Pathology" on Thursday, December 12 at 12PM ET.

Related resources:

About Proscia
Proscia is an AI software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries. Proscia's team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. More information on Concentriq by Proscia can be found here. For more information about the company, visit proscia.com.

SOURCE Proscia

Related Links

http://proscia.com